keine Finanzberatung

GERN · Geron Corporation

Commercial-stage biotech with one approved drug, RYTELO

Risiko 8/10 · HIGH RISK · single-drug biotech · $1.57 ▲ 3.97%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $1.57
  • Market cap $1.0B
  • P/E (ttm) n/a
  • Div yield none
  • 52-wk range $1.04 – $2.01

Wichtigste Risiken

  • RYTELO launch undershoots its first revenue guidance (Shareholders) — EXTREME
  • Single-asset concentration with no pipeline fallback (Shareholders) — HIGH
  • Competing MDS therapies erode uptake and pricing (Shareholders) — MED
  • Cash burn forces dilution before profitability (Shareholders) — MED

Fazit

Only for investors comfortable holding a single-drug launch story where one soft quarter of RYTELO sales rewrites the whole case.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.